RU2505316C2 - Способ визуализации - Google Patents

Способ визуализации Download PDF

Info

Publication number
RU2505316C2
RU2505316C2 RU2010119187/15A RU2010119187A RU2505316C2 RU 2505316 C2 RU2505316 C2 RU 2505316C2 RU 2010119187/15 A RU2010119187/15 A RU 2010119187/15A RU 2010119187 A RU2010119187 A RU 2010119187A RU 2505316 C2 RU2505316 C2 RU 2505316C2
Authority
RU
Russia
Prior art keywords
compound
group
formula
moiety
acid
Prior art date
Application number
RU2010119187/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010119187A (ru
Inventor
Сала ЧЕТТИБИ
Бен НЬЮТОН
Магне СОЛЬБАККЕН
Original Assignee
Джи-И Хелткер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи-И Хелткер Лимитед filed Critical Джи-И Хелткер Лимитед
Publication of RU2010119187A publication Critical patent/RU2010119187A/ru
Application granted granted Critical
Publication of RU2505316C2 publication Critical patent/RU2505316C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2010119187/15A 2007-11-19 2008-11-19 Способ визуализации RU2505316C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98884007P 2007-11-19 2007-11-19
GB0722650.9 2007-11-19
GB0722650A GB0722650D0 (en) 2007-11-19 2007-11-19 Novel imaging method
US60/988,840 2007-11-19
PCT/EP2008/065824 WO2009071444A2 (en) 2007-11-19 2008-11-19 Novel imaging method

Publications (2)

Publication Number Publication Date
RU2010119187A RU2010119187A (ru) 2011-12-27
RU2505316C2 true RU2505316C2 (ru) 2014-01-27

Family

ID=38896533

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010119187/15A RU2505316C2 (ru) 2007-11-19 2008-11-19 Способ визуализации

Country Status (8)

Country Link
US (1) US8834843B2 (enExample)
EP (1) EP2219681A2 (enExample)
JP (1) JP5709522B2 (enExample)
CN (1) CN101951964B (enExample)
BR (1) BRPI0820430A2 (enExample)
GB (1) GB0722650D0 (enExample)
RU (1) RU2505316C2 (enExample)
WO (1) WO2009071444A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571486C1 (ru) * 2014-11-05 2015-12-20 Общество с ограниченной ответственностью "ДИАМЕД" Способ визуализации воспалений

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967704A4 (en) * 2019-06-11 2022-08-31 FUJIFILM Corporation CYCLIC PEPTIDE, CELLULAR SCAFFOLDING MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2005012335A1 (en) * 2003-07-30 2005-02-10 Amersham Health As Imaging agents
WO2006054904A2 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
US20070128174A1 (en) * 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004014795D1 (de) * 2003-10-01 2008-08-14 Merck Patent Gmbh Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
WO2006073314A1 (en) 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
US20080206151A1 (en) 2005-04-25 2008-08-28 Alan Cuthbertson Liposomes
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007148074A1 (en) 2006-06-21 2007-12-27 Hammersmith Imanet Limited Chemical methods and apparatus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2005012335A1 (en) * 2003-07-30 2005-02-10 Amersham Health As Imaging agents
WO2006054904A2 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
US20070128174A1 (en) * 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BATALLER R. «Liver fibrosis» The Journal of Clinical Investigation, vol.111, No.2, 2005. *
BATALLER R. «Liver fibrosis» The Journal of Clinical Investigation, vol.111, №2, 2005. SHI-LIN DU «Cyclic RGD Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats» THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, v.322, № 2, 2007 [онлайн]. [Найдено 04.12.2012]. Найдено в Интернет <URL:http://jpet.aspetjournals.Org/content/322/2/560.full.pdf+html>. *
SHI-LIN DU «Cyclic RGD Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats» THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, v.322, No. 2, 2007 [онлайн]. [Найдено 04.12.2012]. Найдено в Интернет . *
ДАЙСОН Г., МЕЙ П. Химия синтетических лекарственных веществ, пер. с англ. - М.: Мир, 1964. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571486C1 (ru) * 2014-11-05 2015-12-20 Общество с ограниченной ответственностью "ДИАМЕД" Способ визуализации воспалений

Also Published As

Publication number Publication date
WO2009071444A2 (en) 2009-06-11
GB0722650D0 (en) 2007-12-27
WO2009071444A9 (en) 2009-10-01
JP2011506273A (ja) 2011-03-03
BRPI0820430A2 (pt) 2015-05-26
CN101951964B (zh) 2013-05-29
JP5709522B2 (ja) 2015-04-30
RU2010119187A (ru) 2011-12-27
CN101951964A (zh) 2011-01-19
US8834843B2 (en) 2014-09-16
EP2219681A2 (en) 2010-08-25
US20100316565A1 (en) 2010-12-16
WO2009071444A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CN101454026B (zh) 成像剂
Sancho et al. Bombesin receptor-mediated imaging and cytotoxicity: review and current status
Virgolini et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs
US20190365931A1 (en) Double-labeled probe for molecular imaging and use thereof
US8628750B2 (en) Cancer imaging and treatment
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
US20080267882A1 (en) Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy
US20110280802A1 (en) Linkers For Radiopharmaceutical Compounds
EA037778B1 (ru) Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы
CZ20032564A3 (cs) Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků
CN104768573A (zh) 用于位点特异性uPAR靶向的177-Lu标记肽
JP2012207027A (ja) 造影剤
JP2011520971A (ja) ガストリン放出ペプチド化合物
US8568689B1 (en) uPAR-targeting contrast agents
JP2010513476A (ja) 造影剤
RU2505316C2 (ru) Способ визуализации
JP2025516759A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド
US20240115744A1 (en) Fibrin-binding compounds for imaging and treatment
JP2008509921A (ja) 内皮特異的な生体内伝達のターゲティング剤としての熱ショックタンパク質
AU2010258599B2 (en) PET imaging of fibrogenesis
KR20230028412A (ko) 섬유증의 진단 및/또는 모니터링에 사용하기 위한 신규 화합물

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141120